SkinCure Oncology Introduces FDA-Cleared GentleBeam

SkinCure Oncology, the industry leader in providing a comprehensive cancer centre model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure ExperienceSM, announced the addition of FDA-cleared GentleBeam to its treatment platform. GentleBeam enhances SkinCure Oncology's support for dermatology practices, providing an advanced visualisation tool designed to maximise precision in treatment planning, daily dose delivery, and confirmation of tumour eradication.

SkinCure Oncology Chief Executive Officer Kerwin Brandt explained, "GentleBeam's imaging component uses laser-induced technology to generate acoustic pressure waves that help the physician and radiation therapist visualise skin layers and blood vessels. This Photosonic technology enables a more precise definition of treatment areas, which should improve treatment outcomes."

Brandt added, "We are proud to provide our practice partners with the GentleCure radiation-based technology, supported by published studies demonstrating cure rates exceeding 99 per cent for appropriately selected nonmelanoma skin cancers. The addition of GentleBeam demonstrates our commitment to steadily upgrading our technologies and services to provide state-of-the-art IGSRT solutions for the dermatology setting."

Daniel Ladd, DO, Chief Medical Officer of SkinCure Oncology, added, "Radiation therapy in the dermatology setting, when performed using image guidance and following a cancer centre-level model of care, has been shown to provide better cure rates than hospital-based treatment using electron beam therapy, and at a far lower price point for both health insurance providers and patients. GentleBeam, with its expected improvements in planning and treatment precision, will help to widen that gap. The addition of GentleBeam strengthens our ability to personalise treatment and further elevate the GentleCure Experience for every patient."